Exploring Personalized Treatment Using Molecular Profiling and Team Consultation for Women with Recurrent Ovarian, Cervical, or Endometrial Cancer

What this Trial Is About

Researchers are investigating whether genomic sequencing combined with molecular tumor boards can improve treatment responses in patients with recurrent ovarian, cervical, or endometrial cancer. This real-world observational study has two parts a retrospective analysis of past patients treated since January 2022, and a prospective study enrolling 200 patients to observe personalized treatment plans guided by molecular profiling and multidisciplinary consultation. In the retrospective part, data such as tumor genomic sequences, medical histories, treatment recommendations, and therapies used will be reviewed. The prospective part involves collecting tumor tissue and blood samples for next-generation sequencing to determine molecular profiles. An expert panel will suggest individualized treatments based on these profiles and patient data, while attending physicians will finalize treatment plans considering patient preferences, comorbidities, medication risks, insurance coverage, and available clinical trials. Participants will be followed for clinical outcomes, including overall response rates assessed after treatment cycles of 21 to 28 days. Researchers will also track progression-free survival and overall survival over two years. The study includes multidisciplinary consultations and molecular profiling to evaluate the effectiveness of personalized therapies, with the aim of improving care for patients with recurrent gynecological cancers.

A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB